PMID- 23082962
OWN - NLM
STAT- MEDLINE
DCOM- 20140307
LR  - 20220310
IS  - 1755-5922 (Electronic)
IS  - 1755-5914 (Linking)
VI  - 31
IP  - 4
DP  - 2013 Aug
TI  - Updating the relationship between hyperhomocysteinemia lowering therapy and 
      cardiovascular events.
PG  - e19-26
LID - 10.1111/1755-5922.12014 [doi]
AB  - Hyperhomocysteinemia (Hhcy) was defined as an independent risk factor for 
      cardiovascular events. A number of clinical trials had investigated the 
      relationship between Hhcy lowering treatment and cardiovascular diseases, 
      however, the results of these studies remain controversial. This review article 
      gave an over view of the homocysteine metabolisms and updated the recently 
      published results in the role of Hhcy lowering therapy on cardiovascular events.
CI  - (c) 2012 John Wiley & Sons Ltd.
FAU - Cheng, Xiaoshu
AU  - Cheng X
AD  - Department of Cardiology, Second Affiliated Hospital, Nanchang University, 
      Nanchang, China. xiaoshu.cheng@gmail.com
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Cardiovasc Ther
JT  - Cardiovascular therapeutics
JID - 101319630
RN  - 0 (Biomarkers)
RN  - 0LVT1QZ0BA (Homocysteine)
SB  - IM
MH  - Animals
MH  - Biomarkers/blood
MH  - Cardiovascular Diseases/blood/etiology/*prevention & control
MH  - Homocysteine/*blood
MH  - Humans
MH  - Hyperhomocysteinemia/blood/complications/diagnosis/*drug therapy
MH  - Risk Factors
MH  - Treatment Outcome
OTO - NOTNLM
OT  - B vitamin
OT  - Cardiovascular disease
OT  - Folic acid
OT  - Homocysteine
EDAT- 2012/10/23 06:00
MHDA- 2014/03/08 06:00
CRDT- 2012/10/23 06:00
PHST- 2012/10/23 06:00 [entrez]
PHST- 2012/10/23 06:00 [pubmed]
PHST- 2014/03/08 06:00 [medline]
AID - 10.1111/1755-5922.12014 [doi]
PST - ppublish
SO  - Cardiovasc Ther. 2013 Aug;31(4):e19-26. doi: 10.1111/1755-5922.12014.